| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB743G-100UG | |||
| Carrier Free | FAB743A | |||
| Carrier Free | FAB743P | |||
| Carrier Free | AF743-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF349-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-18651-0.02mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB11624-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-43259-0.5mg | |||
| BSA Free | NBP1-43259-0.05mg | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 350 | FAB743U-100UG | |||
| Alexa Fluor 405 | FAB743V-100UG | |||
| Alexa Fluor 532 | FAB743X-100UG | |||
| Alexa Fluor 594 | FAB743T-100UG | |||
| Alexa Fluor 647 | FAB743R-100UG | |||
| Alexa Fluor 700 | FAB743N-100UG | |||
| Alexa Fluor 750 | FAB743S-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB743-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB349-SP | |||
| Carrier Free | MAB349-500 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 350 | FAB7431U-100UG | |||
| Alexa Fluor 405 | FAB7431V-100UG | |||
| Alexa Fluor 488 | FAB7431G-100UG | |||
| Alexa Fluor 532 | FAB7431X-100UG | |||
| Alexa Fluor 594 | FAB7431T-100UG | |||
| Alexa Fluor 647 | FAB7431R-100UG | |||
| Alexa Fluor 700 | FAB7431N-100UG | |||
| Alexa Fluor 750 | FAB7431S-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB7431-SP | |||
![Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Saphenous vein wall harvested from a patient diagnosed with triple-vessel CAD. Histological sections of a graft wall obtained from a 71-year-old patient who developed early graft failure 11 months after coronary artery bypass grafting. VEGFR-3 (b) is shown to be expressed by immunohistochemical staining in smooth muscle cells of the tunica media (TM) and is strongly present in endothelial cells of the tunica intima (TI). Image collected and cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-9D9-Immunohistochemistry-NBP1-18651-img0011.jpg "Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Saphenous vein wall harvested from a patient diagnosed with triple-vessel CAD. Histological sections of a graft wall obtained from a 71-year-old patient who developed early graft failure 11 months after coronary artery bypass grafting. VEGFR-3 (b) is shown to be expressed by immunohistochemical staining in smooth muscle cells of the tunica media (TM) and is strongly present in endothelial cells of the tunica intima (TI). Image collected and cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9) licensed under a CC-BY license.")
![Western Blot: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Analysis using recombinant human soluble VEGF Receptor 3 as target.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-9D9-Western-Blot-NBP1-18651-img0010.jpg)
![Flow Cytometry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Fig. 1: Flow analysis of VEGFR-3/FLT4 expression in primary human dermal lymphatic endothelial cells (HDLEC).](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-9D9-Flow-Cytometry-NBP1-18651-img0007.jpg)
![Flow Cytometry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Fig. 1: Flow analysis of VEGFR-3/FLT4 expression in primary human dermal mivrovascular endothelial cells (HDMVEC) and human umbilical vein endothelial cells (HUVEC). There is only a very weak expression of VEGFR-3/FLT4 detectable in the HUVECs but a strong one in the HDMVEC.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-9D9-Flow-Cytometry-NBP1-18651-img0006.jpg)
![Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free [NBP1-18651] - Saphenous vein wall harvested from a patient diagnosed with double-vessel CAD showing immunohistochemical staining. VEGF-C (a) & VEGFR-3 (b) reactivity in a graft wall obtained from a 67-year-old patient who developed the early graft restenosis within 7 months after coronary artery bypass grafting (the same patient as mentioned in Fig. 6). VEGF-C is localized exclusively within individual smooth muscle cells of the tunica media (TM). Cells with positive VEGFR-3 expression are situated in endothelial cells of the tunica intima (TI). c Negative control. TA tunica adventitia Image collected & cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-18651_mouse-monoclonal-vegfr3-flt-4-antibody-9d9-310202415363714.jpg)
![Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free [NBP1-18651] - Immunohistochemical staining of an internal thoracic artery & saphenous vein wall harvested from a patient with no evidence of luminal stenosis 12 months after CABG. Immunohistochemical staining of VEGF-C (a) & CAV2 (b) in an internal thoracic artery (ITA) graft & VEGFR-3 (c) in saphenous vein (SV) transplant harvested from a 65-year-old patient diagnosed with triple-vessel CAD. Note that lack of CAV2 expression within smooth muscle cells (SMC) in ITA wall is accompanied by VEGF-C positive expression in the same area. In SV tissue sample harvested from the same patient, no VEGRR-3 expression was found. d Negative control. TI tunica intima, TM tunica media, TA tunica adventitia Image collected & cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-18651_mouse-monoclonal-vegfr3-flt-4-antibody-9d9-310202415394521.jpg)
![Immunohistochemistry-Frozen: VEGFR3/Flt-4 Antibody (AFL4) [NBP1-43259] - VEGFR-3 (green) was detected in murine cancer using VEGFR-3-AlexaFluor488 antibody (1:50; 1 hour) in PBS. Nuclei were stained with DAPI (blue). Tissue was fixed in acetone. Image from a verified customer review using the Alexa Fluor488 version of this VEGFR-3 antibody.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-AFL4-Immunohistochemistry-Frozen-NBP1-43259-img0003.jpg "Immunohistochemistry-Frozen: VEGFR3/Flt-4 Antibody (AFL4) [NBP1-43259] - VEGFR-3 (green) was detected in murine cancer using VEGFR-3-AlexaFluor488 antibody (1:50; 1 hour) in PBS. Nuclei were stained with DAPI (blue). Tissue was fixed in acetone. Image from a verified customer review using the Alexa Fluor488 version of this VEGFR-3 antibody.")
![Flow Cytometry: VEGFR3/Flt-4 Antibody (AFL4) [NBP1-43259] - Surface staining of MC/9 cell line with Anti-Mouse Fc epsilon Receptor I alpha (Fc epsilon R1) FITC (left) and PE (right). Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-AFL4-Flow-Cytometry-NBP1-43259-img0002.jpg)
